Skip to content
Select Peer-Reviewed Publications
Sfanos K.S., Sauvageot J., Fedor H.L., Dick J.D., De Marzo A.M., Isaacs W.B. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate, 68(3):306-320, 2008.
Sfanos K.S., Bruno T.C., Maris C.H., Xu L., Thoburn C.J., De Marzo A.M., Meeker A.K., Isaacs W.B., Drake C.G. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clinical Cancer Research, 14:3254-3261, 2008.
Sfanos K.S., Wilson B.A., De Marzo A.M., Isaacs W.B. Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proceedings of the National Academy of Sciences (PNAS) U.S.A., 106:3443-3448, 2009.
Sfanos K.S., Bruno T.C., Meeker A.K., De Marzo A.M., Isaacs W.B., Drake C.G. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate, 69(15):1694-1703, 2009.
Aloia A.L., Sfanos K.S.*, Isaacs W.B., Zheng Q., Maldarelli F., De Marzo A.M., Rein A. XMRV: A new virus in prostate cancer? Cancer Research, 70:10028-10033, 2010. *Co-first author
Sfanos, K.S., Aloia, A.L., Hicks, J.L., Esopi, D.M., Steranka, J.P., Shao, W., Sanchez-Martinez, S., Yegnasubramanian, S., Burns, K.H., Rein, A., De Marzo, A.M. Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines. PLoS ONE, 6(6): e20874, 2011.
Sfanos, K.S., De Marzo, A.M. Prostate cancer and inflammation: The evidence. Histopathology, 60(1):199-215, 2012.
Sfanos, K.S., Aloia, A.L., De Marzo, A.M., Rein, A. XMRV and prostate cancer: A “final” perspective. Nature Reviews Urology, 9:111-118, 2012.
Mak, T.N., Yu, S.H., De Marzo, A.M., Brüggemann, H., Sfanos, K.S. Multilocus Sequence Typing (MLST) analysis of Propionibacterium acnes isolates from radical prostatectomy specimens. Prostate, 73(7):770-777, 2013.
Shinohara, D.B., Vaghasia, A., Yu, S.H., Mak, T.N., Brüggemann, H., Nelson, W.G., De Marzo, A.M., Yegnasubramanian, S., Sfanos, K.S. A mouse model of chronic prostatic inflammation using a humal prostate cancer-derived isolate of Propionibacterium acnes. Prostate, 73(9):1007-1015, 2013.
Hempel, H.A., Burns, K.H., De Marzo, A.M., Sfanos K.S. Infection of xenotransplanted human cell lines by murine retroviruses: A lesson brought back to light by XMRV. Frontiers in Oncology,3:156, 2013. doi: 10.3389/fonc.2013.00156.
Darshan, M., Zheng,Q., Fedor,H.L., Wyhs, N., Yegnasubramanian, S., Lee, P., Melamed, J., Netto, G.J., Trock, B.J., De Marzo, A.M., Sfanos, K.S. Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate, 74(1): 61-69, 2014.
Sfanos, K.S., Canene-Adams, K., Hempel, H., Yu, S.H., Simons, B., Schaeffer, A., Schaeffer, E., Nelson, W.G., De Marzo, A.M. Bacterial prostatitis enhances 2-amino-1-methyl-6-phenylimidazo [4, 5-β] pyridine (PhIP)-induced cancer at multiple sites. Cancer Prevention Research, 2015 doi:10.1158/1940-6207.CAPR-15-0090.
Yu, S.H., Zheng, Q., Esopi, D., Macgregor-Das, A., Luo, J., Antonarakis, E.S., Drake, C.G., Vessella, R., Morrissey, C., De Marzo, A.M., Sfanos, K.S. A paracrine role for IL-6 in prostate cancer patients: Lack of production by primary or metastatic tumor cells. Cancer Immunology Research, 2015 doi:10.1158/2326-6066.CIR-15-0013.
Hempel H.A., Cuka N.S., Kulac I., Barber J.R., Cornish T.C., Platz E.A., De Marzo A.M., Sfanos K.S. Low intratumoral mast cells are associated with a higher risk of prostate cancer recurrence. Prostate, 2017 DOI:10.1002/pros.23280.
Shrestha E., White, J.R., Yu, S.H., Kulac, I., Ertunc, O., De Marzo, A.M., Yegnasubramanian, S., Mangold, L.A., Partin, A.W., Sfanos, K.S. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. Journal of Urology, 2018 DOI: http://dx.doi.org/10.1016/j.juro.2017.08.001.
Sfanos, K.S., Yegnasubramanian, S., Nelson, W.G., De Marzo, A.M. The inflammatory microenvironment and microbiome in prostate cancer development. Nature Reviews Urology, 2018 DOI:10.1038/nrurol.2017.167.
Porter C.M., Shrestha E., Peiffer L.B., Sfanos K.S. The microbiome in prostate inflammation and prostate cancer. Prostate Cancer and Prostatic Diseases, 2018; 21:345-354.
Sfanos K.S., Markowski M.C., Peiffer L.B., Ernst S.E., White J.R., Pienta K.J., Antonarakis E.S., Ross A.E. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer and Prostatic Diseases, 2018; 21:529-548.
Yu S.H., Maynard J.P., Vaghasia A.M., De Marzo A.M., Drake C.G., Sfanos K.S. A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth. Prostate, 2019; 79(2):215-222.
Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Maleki Vareki S, Pal SK, Sfanos KS. The microbiome and genitourinary cancer: A collaborative review. European Urology. 2019;75(4):637-646.
Peiffer LB, Poynton SL, Ernst SE, Hicks JL, De Marzo AM, Sfanos KS. Inflammation-associated pathologies in a case of prostate schistosomiasis: Implications for a causal role in prostate carcinogenesis. The Prostate, 2019;79(11):1316-1325.
Kassiri B, Shrestha E, Kasprenski M, Antonescu C, Florea LD, Sfanos KS*, Wang M-H. A prospective study of the urinary and gastrointestinal microbiome in prepubertal males. Urology, 2019;131:204-210. *Co-senior author and corresponding author
Porter CM, Haffner MC, Kulac I, Maynard JP, Baena-Del Valle JA, Isaacs WB, Yegnasubramanian S, De Marzo AM, Sfanos KS. Lactoferrin CpG island hypermethylation and decoupling of mRNA and protein expression in the early stages of prostate carcinogenesis. American Journal of Pathology, 2019;189(11):2311-22.
Maynard JP, Ertunc O, Kulac I, Baena-Del Valle JA, De Marzo AM, Sfanos KS. Interleukin-8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Molecular Cancer Research, 2020;18(1):153-165.
Hempel Sullivan H, Heaphy CM, Kulac I, Cuka NS, Lu J, Barber JR, De Marzo AM, Lotan TL, Joshu CE, Sfanos KS. High extra-tumoral mast cell counts are associated with a higher risk of adverse prostate cancer outcomes. Cancer Epidemiology, Biomarkers & Prevention, 2020;29(3):668-75.
Hempel Sullivan H, Maynard JP, Heaphy CM, Lu J, De Marzo AM, Lotan TL, Joshu CE, Sfanos KS. Differential mast cell phenotypes in benign versus cancer tissues and prostate cancer oncologic outcomes. Journal of Pathology, 2021; 253(4):415-426.
Shrestha E, Coulter JB, Guzman W, Ozbek B, Hess MM, Mummert L, Ernst SE, Maynard JP, Meeker AK, Heaphy CM, Haffner MC, De Marzo AM, Sfanos KS. Oncogenic gene fusions in non-neoplastic precursors as evidence that bacterial infection can initiate prostate cancer. Proceedings of the National Academy of Science (PNAS), 2021, 18 (32) e2018976118.
Maynard JP, Lu J, Vidal I, Hicks J, Mummert L, Ali T, Kempski R, Carter AM, Sosa R, Peiffer LB, Joshu CE, Lotan TL, De Marzo AM, Sfanos KS. P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer. Journal of Pathology, 2022, 256(2):149-163.
Peiffer LB, White JR, Jones CB, Slottke RE, Ernst SE, Moran AE, Graff JN, Sfanos KS. Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on Enzalutamide and initiating treatment with anti-PD-1 (Pembrolizumab). Neoplasia, 2022, 32:100822.
